ArticleCells2022
Stem-Cell-Derived β-Like Cells with a Functional PTPN2 Knockout Display Increased Immunogenicity.
Open access · goldAbstract read
In one paragraph
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Molecular Mechanisms and Targeted Therapies of PTPN2 in Metabolic Diseases: A Review.Biomolecules · 2026Review
- PTPN2 deficiency amplifies inflammatory signalling and impairs functional maturation of human stem cell-derived islets.Stem cell research & therapy · 2026Article
- Phosphatases in tumor cell immune escape: a perspective based on the camouflage, coercion, cytoprotection.Frontiers in cell and developmental biology · 2026Review
- Untangling the genetics of beta cell dysfunction and death in type 1 diabetes.Molecular metabolism · 2024Review
- PTPN2 Regulates Metabolic Flux to Affect β-Cell Susceptibility to Inflammatory Stress.Diabetes · 2024Article
- The beta cell-immune cell interface in type 1 diabetes (T1D).Molecular metabolism · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Taylor M TrioloBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-4796-6542
J Quinn MatuschekBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.
Roberto Castro-GutierrezBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.
Ali H ShillehBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-5092-5744
Shane P M WilliamsBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.
Maria S HansenBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-2672-3883
Kristen McDanielBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.
Jessie M BarraBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-6456-9293
Aaron MichelsBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-3766-5244
Holger A RussBarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-5117-2927
University of Colorado Anschutz Medical Campus · US
Funding
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8MRegulation of Pancreatic Islet Cell FateR01DK082590 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2009 to 2026
$7.3MMultiple Autoantigens/Multiple Epitopes of Type 1DMR01DK032083 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI MICHELS, AARON W · 1986 to 2025
$6.9MMolecular Dissection of Insulin Targeting in Anti-Islet AutoimmunityR01DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS, Maki Nakayama · 2013 to 2026
$5.3MTraining in Translational Research of Skin DiseasesT32AR007411 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA, ROOP, DENNIS · 1986 to 2025
$4.8MK12 Career DevelopmentK12DK094712 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI STECK, ANDREA · 2011 to 2021
$4.5MInsulin Specific T Cell Response Shaped by Diabetes Protective MHC Class II MoleculesR01DK108868 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS · 2017 to 2026
$3.6MLocal immune modulation for beta cell replacement therapy in type 1 diabetesR01DK132387 · NIDDK · UNIVERSITY OF FLORIDA · PI PHELPS, EDWARD, RUSS, HOLGER A. · 2022 to 2025
$2.1MPTPN2 mutations affect islet beta cell susceptibility in T1DR01DK125360 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI SUSSEL, LORI · 2020 to 2023
$1.7MImproving human pluripotent stem cell derived beta cell transplantation using genetic lineage tracing.R01DK120444 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI RUSS, HOLGER A. · 2018 to 2021
$1.5MInterdisciplinary Bioengineering Research Training in DiabetesT32DK120520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Richard KP Benninger, KATHRYN M HASKINS · 2020 to 2026
$1.1MAutoantigens targeted by CD8 T cells in type 1 diabetes: from islets to bloodR56DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI MICHELS, AARON W, NAKAYAMA, MAKI · 2019 to 2019
$194kNIAMS NIH HHS T32 AR007411NIDDK NIH HHS DK032083NIDDK NIH HHS DK099317NIDDK NIH HHS DK108868NIDDK NIH HHS K12 DK094712NIDDK NIH HHS K12DK094712NIDDK NIH HHS P30 DK116073NIDDK NIH HHS P30DK116073NIDDK NIH HHS R01 DK032083NIDDK NIH HHS R01 DK082590NIDDK NIH HHS R01DK082590NIDDK NIH HHS R01 DK099317NIDDK NIH HHS R01 DK108868NIDDK NIH HHS R01DK12044NIDDK NIH HHS R01 DK120444NIDDK NIH HHS R01 DK125360NIDDK NIH HHS R01 DK132387NIDDK NIH HHS R01DK132387NIDDK NIH HHS R37 DK032083NIDDK NIH HHS R56 DK099317NIDDK NIH HHS SCR_014393NIDDK NIH HHS T32 DK120520NIDDK NIH HHS UC24 DK1041162NIH HHS 5T32AR007411-35NIH HHS T32 DK 120520
Abstract
Type 1 diabetes is a polygenic disease that results in an autoimmune response directed against insulin-producing beta cells.
Indexed as
Diabetes Mellitus, Type 1Insulin-Secreting CellsPluripotent Stem CellsCell DifferentiationHumansProtein Tyrosine Phosphatase, Non-Receptor Type 2T-LymphocytesProtein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, humanautoimmunityautoreactive TCR transductantsco-cultureCRISPR/Cas9 knockoutdirect differentiationgenetic riskPTPN2stem-cell-derived pancreatic beta cellstype 1 diabetes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.